Researchers Recognized with Presidential Early Career Award for Medical Advancements

On January 14, 2025, nearly 400 early-career scientists were honored with the Presidential Early Career Award for Scientists and Engineers (PECASE) at Fort Detrick, Maryland. PECASE is the highest recognition granted by the federal government to professionals at the beginning of their independent research careers. Several researchers funded by the Congressionally Directed Medical Research Programs (CDMRP) were among the recipients, recognized for their contributions to medical advancements in areas such as spinal cord injury, osteoarthritis, melanoma, influenza, prostate cancer, Parkinson’s disease, and toxic exposure.

Among the awardees, Abidemi Bolu Ajiboye, Ph.D., and his team at Case Western Reserve University received funding from the Spinal Cord Injury Research Program in 2018. Their research focuses on integrating electrical stimulation and brain-computer interfaces to restore movement and sensation in individuals with quadriplegia. Similarly, Ambika Bajpayee, Ph.D., of Northeastern University, utilized a 2016 Peer Reviewed Medical Research Program grant to develop cartilage-penetrating therapeutics aimed at treating osteoarthritis, potentially reducing the need for joint replacement surgeries.

In the field of cancer research, Alexander Gusev, Ph.D., at the Dana-Farber Cancer Institute received a 2023 Melanoma Research Program award to identify biomarkers that could improve treatment decisions for stage III melanoma. Likewise, Antonina Mitrofanova, Ph.D., at Rutgers University, secured a 2023 Prostate Cancer Research Program grant to develop computational algorithms that predict metastatic growth and treatment resistance in castration-resistant prostate cancer.

Other researchers recognized include Paul King, Ph.D., from Monash University, who is investigating repurposed drugs as a treatment for severe influenza with support from a 2021 Peer Reviewed Medical Research Program grant. Ekta Khurana, Ph.D., at Weill Cornell Medical College, is utilizing a 2022 Prostate Cancer Research Program award to study a hormone-resistant subtype of prostate cancer and develop computational methods for patient identification and treatment strategies.

In neurodegenerative research, Miranda Lim, M.D., Ph.D., at the Portland VA Research Foundation, is examining the role of glymphatic system dysfunction in Parkinson’s disease progression through a 2023 Parkinson’s Research Program award. Additionally, Bryan McCranor, Ph.D., and his team at the U.S. Army Medical Research Institute of Chemical Defense received funding from the Toxic Exposures Research Program to develop an inhalation-based therapeutic for lung damage caused by toxic inhalation injuries.

Another notable project, led by Marc Wein, M.D., Ph.D., at Massachusetts General Hospital, is investigating the causes of skeletal fragility in fibrous dysplasia patients, supported by a 2022 Peer Reviewed Medical Research Program grant. These researchers, along with their teams, are contributing to advancements in medical science through CDMRP-funded initiatives.

Article by multiple RFHC contributors, based upon information from Department of Defense.

---